ATE540696T1 - Erbb2-antagonisten für die tumorschmerztherapie - Google Patents

Erbb2-antagonisten für die tumorschmerztherapie

Info

Publication number
ATE540696T1
ATE540696T1 AT05734984T AT05734984T ATE540696T1 AT E540696 T1 ATE540696 T1 AT E540696T1 AT 05734984 T AT05734984 T AT 05734984T AT 05734984 T AT05734984 T AT 05734984T AT E540696 T1 ATE540696 T1 AT E540696T1
Authority
AT
Austria
Prior art keywords
pain therapy
tumor pain
erbb2 antagonists
erbb2
antagonists
Prior art date
Application number
AT05734984T
Other languages
English (en)
Inventor
David B Agus
Original Assignee
David B Agus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David B Agus filed Critical David B Agus
Application granted granted Critical
Publication of ATE540696T1 publication Critical patent/ATE540696T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05734984T 2004-04-08 2005-04-07 Erbb2-antagonisten für die tumorschmerztherapie ATE540696T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56107604P 2004-04-08 2004-04-08
PCT/US2005/011781 WO2005099756A2 (en) 2004-04-08 2005-04-07 ErbB ANTAGONISTS FOR PAIN THERAPY

Publications (1)

Publication Number Publication Date
ATE540696T1 true ATE540696T1 (de) 2012-01-15

Family

ID=35150505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05734984T ATE540696T1 (de) 2004-04-08 2005-04-07 Erbb2-antagonisten für die tumorschmerztherapie

Country Status (7)

Country Link
US (2) US20060034840A1 (de)
EP (1) EP1737489B1 (de)
JP (1) JP4969440B2 (de)
AT (1) ATE540696T1 (de)
AU (1) AU2005232657B2 (de)
CA (1) CA2563341C (de)
WO (1) WO2005099756A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP2902491A1 (de) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO Rezeptor bindendes Protein
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2543384A3 (de) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Behandlung von Zuständen mithilfe von Demyelinisation
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
MX2011004467A (es) 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
LT2729173T (lt) * 2011-07-06 2016-10-10 Sykehuset Sorlandet Hf Egfr taikinių terapija
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
ES2745684T3 (es) 2011-11-23 2020-03-03 Medimmune Llc Moléculas de unión específicas para HER3 y usos de las mismas
US9146207B2 (en) 2012-01-10 2015-09-29 Hzo, Inc. Methods, apparatuses and systems for sensing exposure of electronic devices to moisture
WO2013106253A1 (en) 2012-01-10 2013-07-18 Hzo Inc. Methods, apparatuses and systems for monitoring for exposure of electronic devices to moisture and reacting to exposure of electronic devices to moisture
CA2872226A1 (en) 2012-05-02 2013-11-07 Symphogen A/S Humanized pan-her antibody compositions
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
KR102228358B1 (ko) * 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
AU2014290044B2 (en) * 2013-07-17 2020-10-29 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
EP3581586A1 (de) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Verfahren zur behandlung von frühzeitigem brustkrebs mit trastuzumab-mcc-dm1 und pertuzumab
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
CN110337450B (zh) 2017-03-02 2023-07-25 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
IL299376A (en) 2020-06-29 2023-02-01 Genentech Inc Fixed dose combination of pertuzumab plus transtuzumab
AR125902A1 (es) * 2021-05-21 2023-08-23 Lilly Co Eli Compuestos y métodos dirigidos a epirregulina

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100754049B1 (ko) 1999-06-25 2007-08-31 제넨테크, 인크. 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
AU2003295798B2 (en) * 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
WO2005099756A2 (en) 2005-10-27
EP1737489B1 (de) 2012-01-11
CA2563341A1 (en) 2005-10-27
AU2005232657A1 (en) 2005-10-27
US20060034840A1 (en) 2006-02-16
EP1737489A2 (de) 2007-01-03
JP4969440B2 (ja) 2012-07-04
AU2005232657B2 (en) 2010-12-16
WO2005099756A3 (en) 2006-06-15
JP2007532566A (ja) 2007-11-15
CA2563341C (en) 2014-10-21
US20110064737A1 (en) 2011-03-17
US8333964B2 (en) 2012-12-18

Similar Documents

Publication Publication Date Title
ATE540696T1 (de) Erbb2-antagonisten für die tumorschmerztherapie
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
ZA200701656B (en) Humanized anti-cment antagonists
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
IL258880A (en) Diarylhydantoin compounds
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
GEP20074252B (en) Antibodies to vla-1
PT2100614E (pt) Antagonistas de receptor para tratamento de cancro ósseo metastático
ATE461220T1 (de) Anti-egfr-antikörper
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
MX343227B (es) Anticuerpos anti-erbb3.
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
EA200900767A1 (ru) Антагонистические антитела против ephb3
PE20110549A1 (es) EL COMPUESTO 3-(4-CLORO-2-FLUOROBENCIL)-2-METIL-N-(5-METIL-1H-PIRAZOL-3-IL)-8-(MORFOLINOMETIL)IMIDAZO[1,2-b]PIRIDAZIN-6-AMINA, SUS SALES Y LA COMPOSICION QUE LO COMPRENDE
WO2005065266A3 (en) Di-substituted pyrrolotriazine compounds
TW200603828A (en) Treatment of disorders
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
ATE482212T1 (de) Pyrrolotriazinverbindungen
DE602004029671D1 (de) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit